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The incidence of end-stage renal disease (ESRD) is
increasing in the United States population [1]. Despite
the marked increased risk of ESRD among blacks in the
United States population, population-based estimates
show a comparable prevalence of chronic kidney dis-
ease, defined as an estimated glomerular filtration rate
(GFR) less than 60 mL/min/1.73 m2, among different
ethnic groups within the United States population [2–5].
Among nondiabetic participants in the Third National
Health and Nutrition Examination Survey (NHANES
III), chronic kidney disease was present in 9.2% of white
males, 17.8% of white females, 4.2% of black males, and
6.2% of black females [3].
Anemia is frequently associated with chronic kidney
disease, and when present, serves as an independent
risk factor for cardiovascular morbidity and mortality.
Abramson et al [2] reported that chronic kidney disease
and anemia (hemoglobin <12 g/dL in women and <13
g/dL in men) were independent risk factors for stroke
in a middle-aged community-based population in the
Atherosclerosis Risk in the Community (ARIC) Study,
with a relative risk of 7.49 in those subjects who are ane-
mic and had creatinine clearance <60 mL/min compared
to the nonanemic participants with creatinine clearances
>60 mL/min. Similarly, the combination of anemia and
chronic kidney disease has a significant impact on survival
after acute myocardial infarction in a study of Medicare
recipients in Georgia [6].
The Reasons for Geographic and Racial Differences in
Stroke (REGARDS) incidence and mortality study is a
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population-based cohort study of a representative sam-
ple of participants aged 45 years old and older [7]. The
REGARDS Study is designed to identify factors that con-
tribute to the excess stroke mortality among blacks and
in the Southeastern United States. The purpose of this
report is to describe the prevalence of chronic kidney
disease and anemia, using data collected as an ancillary
study of the REGARDS Study [7], and to compare the
prevalence of chronic kidney disease with previous de-
scriptions of the NHANES III participants [3].
METHODS
Subjects
The REGARDS Study cohort is being recruited from
a stratified random probability sample with 20% of par-
ticipants chosen from the coastal plain of North Car-
olina, South Carolina, and Georgia (the buckle of the
Southeastern stroke belt), 30% from the remainder of
North Carolina, South Carolina, and Georgia, and Ten-
nessee, Mississippi, Alabama, Louisiana, and Arkansas,
(the stroke belt), and 50% from the rest of the continen-
tal United States. Cohort selection was designed so that
one half will be African American and one half white,
and one half male and one half female.
Inclusion criteria
Individuals aged 45 years old and older were eligible
for inclusion in the REGARDS cohort, for which en-
rollment began in February 2003. Beginning on May 10,
2004, the additional measures to assess anemia and re-
nal function were added to the protocol and data from
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then until March 1, 2005 are included in this report. This
“Renal REGARDS” includes additional measurements
of hemoglobin, serum urea nitrogen, and serum albumin,
obtained at the time of the initial home visit, and excludes
8400 participants recruited to the initial REGARDS co-
hort before May 10, 2004. Since a total of 30,000 par-
ticipants will ultimately be recruited to the REGARDS
cohort, the Renal REGARDS will ultimately include ap-
proximately 24,000 participants.
Exclusion criteria
Exclusion criteria for REGARDS participation in-
clude active treatment for cancer; any serious medical
condition which would prevent long-term participation;
cognitive impairment as judged by the interviewer; living
in a nursing home or on the waiting list for a nursing home;
and a language barrier (speaks other than English). Pa-
tients with ESRD were excluded from the present anal-
ysis (N = 28) and participants for whom the required
elements needed for the GFR estimates were missing (N
= 467) were also excluded, leaving 6807 available for this
initial assessment.
Data
Data were obtained from each participant in a mul-
tistep fashion. The participant was first contacted by a
mailing followed by a telephone contact where verbal
informed consent was obtained. A trained interviewer
then conducted a computer-assisted telephone interview
(CATI) to obtain a description of demographic factors,
medical history, cognitive screening, and depression mea-
sures. Subsequently, arrangements were made for an
in-home evaluation by a nurse or health-professional.
During the in-home examination, written informed con-
sent was obtained, blood pressure, height and weight and
anthropometric measurements, urine and blood spec-
imens were obtained, an electrocardiogram was per-
formed, and a medication history collected.
The blood and urine samples were analyzed at a cen-
tral laboratory for serum creatinine and blood glucose,
C-reactive protein, lipid assays, and with aliquots were
archived for future studies. In addition, the Renal RE-
GARDS participants had measurements of hemoglobin,
serum urea nitrogen, and albumin performed. We de-
fined subjects as being diabetic if their fasting glucose
was greater than 126 mg/dL, their nonfasting glucose was
greater than 200 mg/dL, or they self-reported current
treatment for diabetes.
We estimated the GFR (mL/min/1.73 m2) using the
six-variable Modification of Diet in Renal Disease study
(MDRD) equation [8]:
Estimated GFR = 170
×[serum creatinine (mg/day)]−0.999
×(age)− 0.176 × (0.762 if female)
×(1.18 if African American)
×[serum urea nitrogen (mg/dL)]−0.170
×[serum albumin (g/dL)]+0.318
Statistical analysis
We used descriptive analyses, including means and pro-
portions. The National Kidney Foundation’s Kidney Dis-
ease Outcomes Quality Initiative’s (NKD/KDOQI) defi-
nition of chronic kidney disease is persistent change (>90
days) in GFR [9], but only single determinations of cre-
atinine, serum urea nitrogen, and albumin were avail-
able for the Renal REGARDS participants. Neverthe-
less, for these analyses, we defined chronic kidney disease
as estimated GFR < 60 mL/min/1.73 m2, using the single
determination of blood parameters and the six-variable
MDRD equation [8].
RESULTS
There were 6807 participants in the Renal REGARDS
population through March 1, 2005, who were not on dial-
ysis, and who were not missing any of the required ele-
ments for estimated GFR determination. The Renal RE-
GARDS participants’ mean (SD) age was 65.5 ± 9.3 (SD)
years, and 88% of the participants were in their sixth
to eighth decade of life. Of the 6807 participants, 4053
(60%) were white and 2925 participants (43%) were male
(Table 1).
Chronic kidney disease, defined as estimated GFR <
60 mL/min/1.73 m2, was present in 1081 (16%) of the
participants (Table 1). The prevalence of chronic kidney
disease increased with increasing age; nine of 316 (3%)
participants, 40 to 49 years old, had chronic kidney dis-
ease; 122 of 1738 (7%) participants, 50 to 59 years old, had
chronic kidney disease; 366 of 2630 (14%) participants,
60 to 69 years old, had chronic kidney disease; 399 of 1653
(24%) participants, 70 to 79 years old, had chronic kidney
disease; and 185 of 470 (39%) participants aged 80 years
and older had chronic kidney disease.
The prevalence of anemia was greater in participants
with chronic kidney disease at all age, ethnic, and gender
strata (Table 1); the average (SD) hemoglobin for partici-
pants with chronic kidney disease was 13.0 g/dL (1.6), and
13.9 g/dL (1.4) for those who did not have chronic kidney
disease. There was no discernible association of age with
measured hemoglobin in the participants without chronic
kidney disease, but in those with chronic kidney disease,
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Table 1. Characteristics of the Renal Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study participants
Number (%) Number (%) Average Average hemoglobinb
with chronic without chronic hemoglobinb in without chronic
kidney kidney chronic kidney kidney diease
Number (%) diseasea disease diease mean (SD) mean (SD)
Total 6807 1081 (16) 5726 (84) 13.0 (1.6) 13.9 (1.4)
Age strata
40–49 years 316 (5) 9 (3) 307 (97) 13.6 (0.8) 13.9 (1.6)
50–59 years 1738 (26) 122 (7) 1616 (93) 13.1 (1.7) 13.9 (1.4)
60–69 years 2630 (39) 366 (14) 2264 (86) 13.0 (1.6) 14.0 (1.4)
70–79 years 1653 (24) 399 (24) 1254 (76) 13.1 (1.6) 13.8 (1.4)
≥80 years 470 (7) 185 (39) 285 (61) 12.9 (1.3) 13.6 (1.5)
Race
White 4053 (60) 687 (17) 3366 (83) 13.4 (1.5) 14.3 (1.3)
Black 2754 (40) 394 (14) 2360 (86) 12.4 (1.6) 13.4 (1.4)
Gender
Male 2925 (43) 384 (13) 2541 (87) 13.7 (1.7) 14.6 (1.3)
Female 3882 (57) 697 (18) 3185 (82) 12.7 (1.4) 13.3 (1.2)
aChronic kidney disease defined as estimated glomerular filtration rate (GFR) <60 mL/min/1.73 m2.
bAverage hemoglobin (g/dL) ± SD.
Table 2. Chronic kidney disease prevalence in nondiabetic Renal Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
and the Third National Health and Nutrition Examination Survey (NHANES III) participants by age strata
Renal REGARDS NHANES IIIa
Number (% of the relevant age, gender, and ethnic group) Number (% of the relevant age, gender, and ethnic group)
(95% CI) (95% CI)
White Black White Black
Males Females Males Females Males Females Males Females
Age Strata (N = 1548) (N = 1898) (N = 718) (N = 1250) (N = 2729) (N = 2882) (N = 845) (N = 729)
All 176 (11.4) 345 (18.2) 62 (8.6) 157 (12.6) 721 (26.4) 1085 (37.6) 101 (12.0) 145 (15.6)
(9.8, 13.0) (16.5, 19.9) (6.5, 10.7) (10.8, 14.4) (24.7, 28.1) (35.8, 39.4) (9.8, 14.2) (13.0, 18.2)
40–49 years 1 (1.4) 2 (2.4) 2 (4.4) 2 (2.8) 26 (3.7) 88 (12.1) 4 (1.4) 9 (2.2)
(0, 4.1) (0, 5.7) (0, 10.3) (0, 6.6) (2.3, 5.1) (9.7, 14.5) (1.0, 2.7) (0.7, 3.7)
50–59 years 12 (3.7) 34 (6.5) 9 (4.2) 18 (5.1) 66 (13.5) 130 (22.9) 10 (6.0) 14 (7.1)
(1.7, 5.7) (4.4, 8.6) (1.5, 6.9) (2.8, 7.4) (10.5, 16.5) (19.4, 26.4) (2.3, 9.7) (3.6, 10.6)
60–69 years 48 (8.1) 128 (17.6) 23 (8.9) 57 (12.0) 179 (27.2) 246 (40.0) 36 (17.1) 56 (29.7)
(5.9, 10.3) (14.8, 20.4) (5.5, 12.3) (9.1, 14.9) (23.8, 30.6) (36.1, 43.9) (12.0, 22.2) (23.2, 36.2)
70–79 years 76 (18.1) 123 (28.2) 16 (10.5) 56 (20.0) 199 (42.4) 307 (56.9) 40 (31.5) 38 (36.6)
(14.4, 21.8) (24.0, 32.4) (5.6, 15.4) (15.3, 24.7) (37.9, 46.9) (52.7, 61.1) (23.5, 39.5) (27.3, 45.9)
≥80 years 39 (29.1) 58 (45.3) 12 (27.9) 24 (32.9) 251 (62.1) 314 (72.1) 11 (35.0) 28 (63.3)
(21.4, 36.8) (36.7, 53.9) (14.5, 41.3) (22.1, 43.7) (57.4, 66.8) (67.9, 76.3) (18.5, 51.5) (48.9, 77.4)
aData extracted from Figure 1 in reference [3].
there was a trend for lower average hemoglobin levels
with increasing age (Table 1).
Of the 6807 Renal REGARDS participants, 1395
(20%) had diabetes. Chronic kidney disease was more
prevalent among the diabetic participants (341 of 1395)
(24.4%) than nondiabetic (749 of 5412) (13.7%). The
prevalence of chronic kidney disease in the nondiabetic
participants is shown in Table 2 by age strata, race, and
gender, with 95% CIs for the proportions. Chronic kid-
ney disease was present in 11.4% of white males, 18.2%
of white females, 8.6% of black males, and 12.6% of black
females. The prevalence of chronic kidney disease in-
creased progressively with age in each of the gender and
ethnic strata, and the prevalence of chronic kidney dis-
ease in females generally exceed that in males, especially
in participants 60 years or older.
DISCUSSION
The United States Renal Data System has documented
persistent excess among blacks in the age-gender ad-
justed incidence and point prevalence ESRD rates. In
2002, the ESRD incidence rates were 982 and 256 per-
sons per million, among blacks and whites, respectively,
a 3.8-fold excess risk of ESRD for blacks [1]. Rates for
cause-specific ESRD, including disease attributable to hy-
pertension and diabetes (which account for over 70%
of incident ESRD in the United States) show similar
racial disparities [1]. Examination of large cohorts of par-
ticipants, like REGARDS and NHANES III can pro-
vide population estimates of the prevalence of chronic
kidney disease, with the implication being that the inci-
dence of ESRD is driven by the chronic kidney disease
prevalence.
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The overall prevalence of chronic kidney disease in
the currently recruited Renal REGARDS cohort is ap-
proximately 16%, (Table 1). There was a slight excess of
chronic kidney disease in white compared to black partic-
ipants (17% versus 14%), and in the females compared
to the males (18% versus 13%) (Table 1). The prevalence
of chronic kidney disease (based on a single creatinine,
serum urea nitrogen, and serum albumin measurement)
increased with the age strata of the Renal REGARDS
participants (Table 1). There were no major associations
of gender and ethnicity with average hemoglobin. The ex-
pected relationship between chronic kidney disease and
hemoglobin was observed, with the average hemoglobin
(SD) of 13.0 (1.6) g/dL in the participants with chronic
kidney disease and 13.9 (1.4) g/dL in the non-chronic kid-
ney disease Renal REGARDS participants. It is not sur-
prising that chronic kidney disease was more prevalent
among diabetic participants (24.4%), than among nondi-
abetic participants (13.7%).
Our observations for the current nondiabetic Renal
REGARDS participants are compared to the chronic
kidney disease prevalence reported for nondiabetic par-
ticipants from the NHANES III study in Table 2. Clase,
Garg, and Kiberd [3] reported that the prevalence of
chronic kidney disease in an analysis of NHANES III;
among adults aged 20 years and older, 9.2% for white
men; 17.8% for white women; 9.2% for black men; and
6.3% for black women. When their analysis was limited
to nondiabetic whites and blacks, and subjects aged 40
years and older, the observed prevalence of chronic kid-
ney disease was 26.4% for white males, 37.6% for white
females, 12.0% for black males, and 15.6% for black fe-
males (Table 2). As is also seen in Table 2, the prevalence
of chronic kidney disease in the Renal REGARDS par-
ticipants was much lower at almost all ages. When the
gender and ethnic strata were compared with their 95%
CIs, the prevalence for chronic kidney disease in the white
Renal REGARDS participants are less than half of the
NHANES III results, and these 95% CIs do not overlap.
The same pattern is seen comparing the black partici-
pants in the two studies, but the 95% CIs overlap. The
study design and recruitment strategy were not the same
for the two studies; specifically, the recruitment strategy
for REGARDS included adults 45 years of age or older,
with equal representation of blacks and whites, males and
females, and a broad geographic base. The recruitment
strategy for NHANES III included younger participants
than the REGARDS study. Our preliminary analysis sug-
gests that the prevalence of chronic kidney disease among
the current Renal REGARDS participants may surpris-
ingly be much less than is reported in the NHANES III
samples of nondiabetics by Clase, Garg, and Kiberd [3]
(Table 2). We used the MDRD equation [8] to estimate
kidney function for the Renal REGARDS participants.
Estimated GFR using the four-variable MDRD equation
will be available for the entire REGARDS cohort, but
for the analysis of Renal REGARDS, the six-variable
MDRD equation [8] is being used because serum albumin
and serum urea nitrogen, in addition to creatinine, are
available. While considerable controversy exists about
the most appropriate estimating equations for estimated
GFR [3, 4], we have used the same estimating GFR equa-
tion as Clase, Garg, and Kiberd [3] for the comparisons
of the data presented in Table 2. Formal, adjusted com-
parisons of the two populations will await the completion
of recruitment for the REGARDS Study.
There are strengths to our study that should be noted.
Most important, REGARDS is a unique sample of the
United States population, with a recruitment strategy
that emphasizes the population (blacks and Southeast-
ern United States) at risk for stroke. Second, we limited
our sample to individuals aged 45 years and older, the
portion of the United States population most at risk of
chronic kidney disease and ESRD. This allows us to ex-
amine patterns and risk factors for moderate to severe
chronic kidney disease with sufficient numbers of cases
to provide statistically stable estimates of effect. The ad-
dition of hemoglobin measurements, and albumin and
serum urea nitrogen in the Renal REGARDS cohort,
and the use of a single central laboratory for all analy-
ses will permit more precise determinations of estimated
GFR, and a prospective assessment of the independent
risk of anemia for stroke, chronic kidney disease, and car-
diovascular disease. As will be the case for most large epi-
demiologic efforts, a limitation of the REGARDS Study
is that GFR must be estimated rather than directly mea-
sured. This is due to the expense and inherent difficulties
in measuring GFR or collecting accurate creatinine clear-
ances in a population of 30,000 participants. Furthermore,
the single determination of serum creatinine and serum
urea nitrogen supports a single estimate of the GFR, and
does not formally fulfill the precise definition of chronic
kidney disease, according to the KDOQI guidelines of
the National Kidney Foundation [9]. If follow-up home
visits and repeat blood samples become possible, then the
associated risk factors for stroke, chronic kidney disease,
and cardiovascular disease could be related to the pro-
portion of the participants who showed changes in their
kidney function over time.
CONCLUSION
We have described a large, unique cohort of partici-
pants who have been identified to be at relatively high risk
for incident stroke, chronic kidney disease, and cardiovas-
cular disease. In the participants who are balanced with
respect to gender and white or black ethnicity, the preva-
lence of chronic kidney disease is higher in the higher
age strata. Not surprisingly, the average hemoglobin is
lower in the presence of chronic kidney disease, defined
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as estimated GFR <60 mL/min/1.73 m2. Whether or not
there are associations between the prevalence of chronic
kidney disease, anemia, and stroke, as suggested by the
previous ARIC Study [2], are important public health
questions that the REGARDS Study will specifically ad-
dress.
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